Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 & RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.

Patents 152show all

  • 48
    A61K - Preparations for medical, dental, or toilet purposes
  • 14
    C07D - Heterocyclic compounds
  • 12
    C08F - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
  • 8
    B82Y - Specific uses or applications of nanostructures
  • 4
    C12N - Microorganisms or enzymes
  • 2
    C07H - Sugars
  • 2
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 2
    C12Y - Enzymes

Clinical Trials 9show all

5Phase 24Phase 1/Phase 2

SEC Filings show all


115
8-K

37
10-Q

12
10-K

1
D

Contact Information

15245 Shady Grove Road Suite 455
Rockville, MD 20850
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$5,000,00011-502013-10-13Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2013-10-13$5,000,000Series Unknown

SEC Form D Funding Events

DateOfferedSoldType
2008-01-08Unknown Unknown Other (Paper Filing)